J&J Quits RSV Development With Two Rivals Already Poised For US Approval
The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.
You may also be interested in...
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.